Clinical Trials Sponsored by Galera Therapeutics, Inc.

Total 3030 results

Impact Therapeutics, Inc.

Completed

A Study of IMP4297 in Patients With Advanced Solid Tumors

Breast Cancer | Ovarian Cancer | Prostate Cancer | Advanced Solid Tumours

China
Emergo Therapeutics, Inc.

Completed

Norketotifen for the Treatment of Uncomplicated Influenza-like Illness

Influenza -Like Illness

United States
Magenta Therapeutics, Inc.

Terminated

A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456 (IMD-002)

Inherited Metabolic Disorders (IMD)

United States
Vyne Therapeutics Inc.

Completed

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

Acne Vulgaris

United States
Hengrui Therapeutics, Inc.

Unknown

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

Breast Cancer | Gastric Cancer | NSCLC | Solid Tumors

United States
Sarepta Therapeutics, Inc.

Completed

Study of Eteplirsen in DMD Patients (PROMOVI)

Duchenne Muscular Dystrophy (DMD)

United States
Lisata Therapeutics, Inc.

Withdrawn

CLBS119 for Repair of COVID-19 Induced Pulmonary Damage

Covid-19

United States
Clarus Therapeutics, Inc.

Completed

Pharmacokinetic Study to Determine Time to Steady-state

Male Hypogonadism | Secondary Hypogonadism | Primary Hypogonadism

United States
Aclaris Therapeutics, Inc.

Completed

A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Androgenetic Alopecia

United States
Aclaris Therapeutics, Inc.

Completed

Study of A-101 for the Treatment of Seborrheic Keratosis

Seborrheic Keratosis

United States
Peloton Therapeutics, Inc.

Completed

A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets

Healthy

United States
Iconic Therapeutics, Inc.

Completed

Safety and Tolerability Study for Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Leap Therapeutics, Inc.

Completed

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

Solid Tumors

United States
GSNOR Therapeutics, Inc.

Unknown

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)
Iconic Therapeutics, Inc.

Completed

Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (EMERGE)

Age-related Macular Degeneration | Choroidal Neovascularization

United States
Aclaris Therapeutics, Inc.

Completed

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

Alopecia

United States
Galectin Therapeutics Inc.

Completed

An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis

Psoriasis

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Uremic Pruritus

United States
Pearl Therapeutics, Inc.

Completed

A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010

Chronic Obstructive Pulmonary Disease

United States
Aclaris Therapeutics, Inc.

Terminated

A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata

Alopecia Areata

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

COPD

Japan
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Conjunctivitis, Allergic

Canada
Renibus Therapeutics, Inc.

Withdrawn

RBT-1 Phase 1b Clinical Trial in Healthy Volunteers and Subjects With CKD

Acute Kidney Injury
Obalon Therapeutics, Inc.

Unknown

Obalon Balloon System Post-Approval Study (PAS)

Obesity

United States
Tenax Therapeutics, Inc.

Completed

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF (HELP)

Heart Failure With Normal Ejection Fraction | Heart Failure, Right Sided | Hypertension Pulmonary Secondary

United States
Esperion Therapeutics, Inc.

Completed

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Diabetes Mellitus, Type 2 | Diabetes | Cholesterolemia

United States
BlackThorn Therapeutics, Inc.

Completed

BTRX-246040 Study in Subjects With Parkinson's Disease With Motor Fluctuations

Parkinson Disease | Motor Disorder

United States
Proteostasis Therapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United Kingdom
Sarepta Therapeutics, Inc.

Completed

Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy

Muscular Dystrophy, Duchenne

United States
Sarepta Therapeutics, Inc.

Completed

Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients

Duchenne Muscular Dystrophy

United States
Impact Therapeutics, Inc.

Completed

IMP4297 Food Effect Trial in Healthy Volunteers

Solid Tumor

China
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

Dermatosis Papulosa Nigra

United States
Proteostasis Therapeutics, Inc.

Completed

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy

Cystic Fibrosis

United Kingdom
Avenue Therapeutics, Inc.

Completed

Tramadol Versus Placebo in the Management of Postoperative Pain Following Bunionectomy

Pain Management

United States
Velicept Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

Overactive Bladder

United States
Novus Therapeutics, Inc

Completed

Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers

Healthy Adult Volunteers

United States
Repurposed Therapeutics, Inc.

Unknown

Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness

Motion Sickness

United States
Impact Therapeutics, Inc.

Unknown

A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer (FLAMES)

Ovarian Cancer

China
Realm Therapeutics, Inc.

Completed

Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Denali Therapeutics Inc.

Completed

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

Parkinson Disease

United States
Novus Therapeutics, Inc

Completed

Evaluation of Safety and Pharmacodynamics of OP0201 Compared to Placebo in Healthy Adults

Healthy Adults

Germany
Aclaris Therapeutics, Inc.

Completed

Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

Alopecia Areata | Alopecia Totalis | Alopecia Universalis

United States
Repurposed Therapeutics, Inc.

Completed

Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness

Motion Sickness

United States
Aileron Therapeutics, Inc.

Completed

Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD (telos)

Chronic Obstructive Pulmonary Disorder

United States, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Czechia
Vyne Therapeutics Inc.

Completed

Dermal Cumulative Irritant Patch Study

Healthy
Pearl Therapeutics, Inc.

Terminated

Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD

COPD

United States
Vyne Therapeutics Inc.

Completed

A Randomized, Controlled Study to Evaluate the Sensitizing Potential of FMX-101 in Healthy Volunteers Using a Repeat Insult Patch Test Design

Healthy
Relmada Therapeutics, Inc.

Completed

Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone)

Neuropathic Pain
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

COPD, Chronic Obstructive Pulmonary Disease

Belgium

3

Subscribe